GlassScriptPhysician profile
Ghassan A Atto
NPI 1558561720
$5,684.26
in general payments reported to CMS, 2019-2025
48 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $652 · 2021: $1,943 · 2022: $626 · 2023: $701 · 2024: $595 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Education: $25.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.20 |
| Education | $25.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,477.99 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $668.15 | 2020-2025 | Airsupra, Breztri |
| E.R. Squibb & Sons, L.L.C. | $480.73 | 2019-2025 | Eliquis, Camzyos, Cobenfy |
| Neurocrine Biosciences, INC. | $342.69 | 2021-2025 | Ingrezza |
| Novo Nordisk INC | $272.02 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $261.24 | 2021 | |
| Lilly USA, LLC | $244.21 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $180.94 | 2020 | |
| Avanir Pharmaceuticals, INC. | $152.02 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.36 | 2020-2022 | |
| Astellas Pharma US INC | $125.22 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $106.82 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $95.29 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $84.22 | 2023-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $71.33 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghassan Atto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.